Description: GERM is designed to give direct exposure to the biotech companies directly engaged in the testing and treatments of infectious diseases. Focused on advancements with targeted exposure to the forefront of R&D, vaccines, therapies and testing technologies.
Exchange: NYSE ARCA
Country: US
Currency: US Dollar ($)
Category: Health
| Asset Allocation | |||
|---|---|---|---|
| Asset Class | Long % | Short % | Net Assets |
| Stock US | 79.48 | 0.00 | 79.48 |
| Stock non-US | 20.27 | 0.00 | 20.27 |
| Bond | 4.58 | 0.00 | 4.58 |
| Cash | 0.65 | 4.99 | -4.34 |
| Sector Weights | ||
|---|---|---|
| Sector | Equity % | Relative to Category |
| Healthcare | 100.00 | 99.57 |
| World Regions | ||
|---|---|---|
| Region | Equity % | Relative to Category |
| North America | 84.05 | 92.60 |
| Europe Developed | 5.93 | 4.28 |
| Asia Emerging | 5.18 | 0.82 |
| United Kingdom | 3.97 | 1.65 |
| Japan | 0.76 | 0.54 |
| Africa/Middle East | 0.11 | 0.02 |
| Australasia | 0.00 | 0.11 |